Use of clinical decision-support system can improve HIV care

Use of clinical decision-support system can improve HIV care
Use of a clinical decision-support system appears to be beneficial in HIV care, with improvements noted in CD4 cell counts and clinic follow-up, according to a study published in the Dec. 4 issue of the Annals of Internal Medicine.

(HealthDay)—Use of a clinical decision-support system (CDSS) appears to be beneficial in HIV care, with improvements noted in CD4 cell counts and clinic follow-up, according to a study published in the Dec. 4 issue of the Annals of Internal Medicine.

Gregory K. Robbins, M.D., M.P.H., from Massachusetts General Hospital in Boston, and colleagues examined the efficacy of a CDSS in improving HIV outcomes in a involving 33 HIV care providers who followed 1,011 patients with HIV. In the , interactive computer alerts were generated for virologic failure, suboptimal follow-up, and abnormal test results, which facilitated rescheduling of appointments and repeat laboratory testing (FastTrack). Static alerts were received for the control group.

The researchers found that, in the intervention versus control group, the mean increase was significantly greater (0.0053 versus 0.0032 x 109 cells/L per month; P = 0.040) and the rate of six-month suboptimal follow-up was significantly lower (20.6 versus 30.1 events per 100 patient-years; P = 0.022). In the intervention group, the median time to next scheduled appointment was significantly shorter after a suboptimal follow-up alert (1.71 versus 3.48 months) and after a toxicity alert (2.79 versus >6 months). Adoption of the CDSS as part of standard care was supported by more than 90 percent of providers.

"The principles of FastTrack may readily transfer to other HIV clinical settings and inform the design of systems to support disease management and improve outcomes in HIV as well as other ," the authors write.

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

HIV status doesn't influence Hodgkin's lymphoma outcome

Oct 11, 2012

(HealthDay)—Despite more extensive disease and more adverse prognostic factors, HIV-positive patients with Hodgkin's lymphoma (HL) do not have worse outcomes when treated with doxorubicin, bleomycin, vinblastine, ...

Recommended for you

The genetics of coping with HIV

21 hours ago

We respond to infections in two fundamental ways. One, which has been the subject of intensive research over the years, is "resistance," where the body attacks the invading pathogen and reduces its numbers. Another, which ...

Long acting HIV drugs to be developed

Sep 11, 2014

HIV drugs which only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of 'pill fatigue'.

Puerto Rico partners on US HIV vaccine project

Sep 10, 2014

Puerto Rico's governor says the island's largest public university is partnering with federal agencies to oversee a U.S.-funded project aimed at trying to develop a prophylactic vaccine for the HIV virus that causes AIDS.

User comments